Literature DB >> 3009382

Reversible binding of polymyxin B and neomycin to the solid part of faeces.

M P Hazenberg, A M Pennock-Schröder, J P van de Merwe.   

Abstract

Previous studies have shown that polymyxin B and neomycin were bound to the solid part of human faeces. In the present study, the faecal binding of polymyxin B and neomycin was studied, using a wide range of concentrations of drugs and faecal dilutions. Up to 25 mg of polymyxin B and 15 mg of neomycin could bind to 1 g of faeces but the binding was found to be reversible. With faeces of rats it was found that polymyxin B was mainly bound to the non-bacterial part of faeces, whereas neomycin was bound to the bacterial as well as the non-bacterial part. The implications of the reversible binding of antibiotics to intestinal contents for selective decontamination are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009382     DOI: 10.1093/jac/17.3.333

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  The non-enzymatic inactivation of thirteen beta-lactam antibiotics in human faeces.

Authors:  G Jansen; F Weissing; H de Vries-Hospers; R Tonk; D van der Waaij
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

2.  The in vitro inactivation of thirteen beta-lactam antibiotics by other mechanisms than adsorption to faecal substance.

Authors:  H de Vries-Hospers; G Jansen; R Tonk; D Oenema; D van der Waaij
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

3.  Norfloxacin binds to human fecal material.

Authors:  C Edlund; L Lindqvist; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

4.  A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients.

Authors:  Julie Le Naour; Zsofia Sztupinszki; Vincent Carbonnier; Odile Casiraghi; Virginie Marty; Lorenzo Galluzzi; Zoltan Szallasi; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2022-04-17       Impact factor: 7.723

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.